Literature DB >> 23997064

The role of infection in the pathogenesis of idiopathic pulmonary fibrosis.

Philip L Molyneaux1, Toby M Maher.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive, and invariably fatal, condition that is believed to arise in genetically susceptible individuals as a consequence of an aberrant wound-healing response following repetitive alveolar injury. The exact triggers, which initiate the fibrotic process, remain unknown. Infectious agents, including both viruses and bacteria, have the capacity to cause alveolar-epithelial cell injury and apoptosis. Relatively few studies have examined the role of infection in IPF. Those that have, point to viruses playing a key role as cofactors in the initiation and progression of IPF. There is also some evidence to suggest that viral infection may be responsible for a proportion of acute exacerbations of IPF. The role played by bacteria in the pathogenesis of IPF is less clear cut. Studies from other respiratory diseases suggest that alterations in the lung microbiome are associated with disease and that these changes influence disease behaviour. Emerging molecular microbiological techniques are making the study of microbial communities in the lung easier. It is hoped that by combining such techniques with the careful longitudinal phenotyping of patients with IPF, it will be possible to elucidate the role played by bacteria and viruses in the pathogenesis of the disease. If infection plays a causal role in IPF then it is possible that therapeutic strategies, utilising currently available antiviral or antibiotic drugs, may be effective in modifying the course of this devastating condition.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23997064     DOI: 10.1183/09059180.00000713

Source DB:  PubMed          Journal:  Eur Respir Rev        ISSN: 0905-9180


  53 in total

Review 1.  Fibrosis: ultimate and proximate causes.

Authors:  Victor J Thannickal; Yong Zhou; Amit Gaggar; Steven R Duncan
Journal:  J Clin Invest       Date:  2014-11-03       Impact factor: 14.808

2.  Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study.

Authors:  MeiLan K Han; Yueren Zhou; Susan Murray; Nabihah Tayob; Imre Noth; Vibha N Lama; Bethany B Moore; Eric S White; Kevin R Flaherty; Gary B Huffnagle; Fernando J Martinez
Journal:  Lancet Respir Med       Date:  2014-04-21       Impact factor: 30.700

Review 3.  The respiratory microbiome in idiopathic pulmonary fibrosis.

Authors:  Richard J Hewitt; Philip L Molyneaux
Journal:  Ann Transl Med       Date:  2017-06

Review 4.  Microbiome in chronic obstructive pulmonary disease.

Authors:  Eduard Monsó
Journal:  Ann Transl Med       Date:  2017-06

Review 5.  Promising new treatment targets in patients with fibrosing lung disorders.

Authors:  Martina Sterclova; Martina Vasakova
Journal:  World J Clin Cases       Date:  2014-11-16       Impact factor: 1.337

Review 6.  Associations of the microbiome and esophageal disease.

Authors:  Ikenna Okereke; Catherine Hamilton; Alison Wenholz; Vikram Jala; Thao Giang; Sandy Reynolds; Aaron Miller; Richard Pyles
Journal:  J Thorac Dis       Date:  2019-08       Impact factor: 2.895

Review 7.  Acute exacerbation of idiopathic pulmonary fibrosis-a review of current and novel pharmacotherapies.

Authors:  Maya M Juarez; Andrew L Chan; Andrew G Norris; Brian M Morrissey; Timothy E Albertson
Journal:  J Thorac Dis       Date:  2015-03       Impact factor: 2.895

Review 8.  Microbiome in interstitial lung disease: from pathogenesis to treatment target.

Authors:  Margaret L Salisbury; MeiLan K Han; Robert P Dickson; Philip L Molyneaux
Journal:  Curr Opin Pulm Med       Date:  2017-09       Impact factor: 3.155

9.  MUC5B and Idiopathic Pulmonary Fibrosis.

Authors:  Ivana V Yang; Tasha E Fingerlin; Christopher M Evans; Marvin I Schwarz; David A Schwartz
Journal:  Ann Am Thorac Soc       Date:  2015-11

Review 10.  The evolving role of the lung microbiome in pulmonary fibrosis.

Authors:  Jay H Lipinski; Bethany B Moore; David N O'Dwyer
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-09-02       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.